FDA Approves Maintenance Lenalidomide for Myeloma

February 22nd, 2017 – The FDA has approved lenalidomide as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT), according to Celgene, the manufacturer of the treatment. The data for the approval came from 2 large trials (1000+ patients each) that compared maintenance lenalidomide versus no maintenance after auto-HSCT. The primary endpoint of both studies was progression-free … (leggi tutto)